TRADE NEWS: Agilent Technologies Lists LC and Mass Spec Systems as Class I Medical Devices with FDA

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE:A) today announced that it has listed its Infinity Series 1200 liquid chromatography systems and 6000 Series mass spectrometry systems as Class I medical devices with the U.S. Food and Drug Administration.

“The latest generation of liquid chromatography and mass spec systems that Agilent has registered holds tremendous value for the medical community,” said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. “We’re being very methodical in bringing this technology to the clinic, while ensuring that the equipment meets the laboratories’ needs.”

The Infinity Series1200 is manufactured in Waldbronn, Germany, and the 6000 Series is manufactured in Singapore. Both facilities are registered as medical device establishments with the FDA, a requirement for manufacturing medical devices. In September 2011, those facilities were certified as meeting the internationally recognized ISO 13485 quality-management standard. In June 2011, Agilent’s reagent manufacturing facility in Cedar Creek, Texas, was registered with the FDA as a medical device establishment.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.



CONTACT:

Agilent Technologies Inc.
Stuart Matlow, +1-408-553-7191
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  FDA

MEDIA:

Logo
 Logo

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.